It’s been a huge year for Racura Oncology (ASX:RAC), and CY26 only promises to get bigger as the biotech developer leaves behind its “Race Oncology” name and dives into further developments for next-gen cancer drugs.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This article is disseminated in partnership with Racura Oncology Ltd. It is intended to inform investors and should not be taken as financial advice.
The Market Link reporter Jonathon Davidson spoke to Racura’s executive chairman, Peter Smith, to talk all the latest developments in this Capital Compass. You can watch the full interview in the browser above.
Join the discussion. See what HotCopper users are saying about Racura Oncology Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.